|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term restricted cash | ||||||||||||||||||||
| Investment in equity securities | ||||||||||||||||||||
| Trade and other receivables, net | ||||||||||||||||||||
| Short-term royalty and commercial payment receivables | ||||||||||||||||||||
| Short-term royalty and commercial payment receivables under the EIR method | ||||||||||||||||||||
| Short-term royalty and commercial payment receivables under the cost recovery method | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Long-term restricted cash | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Long-term royalty and commercial payment receivables | ||||||||||||||||||||
| Long-term royalty and commercial payment receivables under the EIR method | ||||||||||||||||||||
| Long-term royalty and commercial payment receivables under the cost recovery method | ||||||||||||||||||||
| Exarafenib milestone asset (Note 6) | ||||||||||||||||||||
| Investment in warrants | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other assets - long term | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued and other current liabilities | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Contingent consideration under RPAs, AAAs, and CPPAs | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Unearned revenue recognized under units-of-revenue method | ||||||||||||||||||||
| Preferred stock dividend accrual | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Contingent value rights liabilities - current portion | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Unearned revenue recognized under units-of-revenue method - long-term | ||||||||||||||||||||
| Exarafenib milestone contingent consideration (Note 6) | ||||||||||||||||||||
| Long-term operating lease liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Contingent value rights liabilities - long-term | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Convertible preferred stock, $0.05 par value, 5,003 shares authorized, issued and outstanding as of March 31, 2026 and December 31, 2025 | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,909,854 and 11,858,955 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities, convertible preferred stock and stockholders' equity | ||||||||||||||||||||
Loading...
